Proton Partners International to Acquire Gulf International Cancer Centre
Proton Partners International has today announced that it has agreed terms for the acquisition of the Gulf International Cancer Centre in Abu Dhabi as part of plans to create the first proton beam therapy treatment centre in the United Arab Emirates.
Proton Partners has signed a sale-and-purchase agreement for the acquisition of the centre from Mediclinic Middle East and the Al Noor Hospitals Group, part of Mediclinic International plc – a FTSE100 listed private hospital group with three operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates.
Proton Partners, The First Investor (part of the Dubai-based Alfardan Group) and the Kuwaiti-based Al Sayer Group will be joint investors in the new Abu Dhabi Proton Centre (ADPC) in Abu Dhabi.
The centre is situated on a site provided by SBK Holding LLC which is the Holding Company of His Highness Dr. Sheikh Sultan Bin Khalifa Bin Zayed Al Nahyan, Advisor to the President of the United Arab Emirates.
The acquisition of the Gulf International Cancer Centre will enable Proton Partners International to provide proton beam therapy treatment in addition to conventional cancer treatments that the centre has offered to date.
Mike Moran MBE, CEO of Proton Partners International, said: “There is a growing need for proton beam therapy treatment around the world and no centres currently offer this in the Middle East. The treatment is transforming the lives of many thousands of cancer patients. We are delighted that the acquisition of the Gulf International Cancer Centre (GICC) means the creation of the first proton beam therapy centre in the United Arab Emirates is fast becoming a reality.
“Proton Partners International is a leading developer of proton beam therapy facilities having recently announced the development of three centres across the UK. We work with world leading technology partners such as IBA, Philips and Elekta, and I am delighted that they are also supporting us in the development of the proton centre in Abu Dhabi.”
David Hadley, CEO of Mediclinic Middle East, said: “The decision to divest GICC has been taken in accordance with a determined strategy for the future of Mediclinic Middle East since the integration of Al Noor Hospitals Group plc into the Group in February 2016. Although tertiary level, specialist services such as those provided by GICC form a key part of Mediclinic’s strategy, the facility in its current form duplicates services which will be provided by our Comprehensive Cancer Centre in Dubai and through our other main hospitals. Following their acquisition of GICC, we welcome the plans of Proton Partners International to introduce proton beam therapy to the UAE, an advanced treatment modality which will be a highly beneficial addition to the services available to cancer sufferers in the country.”